impact factor
logo
 

Full Papers

 

The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13

 

  1. Rheumatology Unit, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
  2. Rheumatology Unit, ASST Fatebenefratelli-Luigi Sacco University Hospital, Milan, Italy. vale.gio@fastwebnet.it
  3. Rheumatology Unit, ASST Fatebenefratelli-Luigi Sacco University Hospital, Milan, Italy.
  4. Rheumatology Unit, ASST Fatebenefratelli-Luigi Sacco University Hospital, Milan, Italy.
  5. Rheumatology Unit, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
  6. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  7. Rheumatology Unit, ATS Sardegna, P. Dettori Hospital, Tempio Pausania, Italy.
  8. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Italy.
  9. Respiratory Unit, L. Sacco University Hospital, ASST Fatebenefratelli-Sacco, Milan, Italy.
  10. Rheumatology Unit, Internal Medicine Department, ASST Settelaghi, Ospedale Di Circolo - Fondazione Macchi, Varese, Italy.
  11. Laboratory of Experimental Biochemistry & Molecular Biology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy, and Department of Athletics, Strength and Conditioning, Poznań University of Physical Education, Poznań, Poland.
  12. Department of Infectious Diseases, ASST-Fatebenefratelli-Luigi Sacco University Hospital, Department of Biochemical and Clinical Sciences “L. Sacco”, University of Milan, Italy.
  13. Rheumatology Unit, ASST Fatebenefratelli-Luigi Sacco University Hospital, Milan, Italy.

CER14048
Full Papers

purchase article

PMID: 33200740 [PubMed]

Received: 17/09/2020
Accepted : 02/11/2020
In Press: 16/11/2020

Abstract

OBJECTIVES:
Fibromyalgia syndrome (FM) is a complex disease that is mainly characterised by chronic widespread pain, fatigue and sleep disturbances and may be precipitated or worsened by many stressors. The aim of this study was to observe the behaviour of FM symptoms during the course of coronavirus disease 2019 (COVID-19).
METHODS:
Patients who had been diagnosed as having FM for ≥3 months were recruited between February and May 2020. The collected data were age, sex, educational level and marital status; height and weight; and the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromyalgia Assessment Status 2019 (FASmod), and the Polysymptomatic Distress Scale (PDS). The patients were divided into those with or without concomitant COVID-19 infection.
RESULTS:
Eight hundred and ninety-seven (93%) of the 965 patients (881 women [91.3%] and 84 men [8.7%]) were followed up on an outpatient basis because of FM and 68 (7.0%) were either followed up as out-patients or hospitalised because of COVID-19. There was no difference in the sociodemographic data of the two groups, but there were statistically significant between-group differences in the results of the clinimetric tests. The major differences between the score of the items (those with the greatest disease impact) were the following related symptoms: sleep quality (FIQR15), fatigue/energy (FIQR13), pain (FIQR12), stiffness (FIQR14).
CONCLUSIONS:
The mean total and subdomain scores of all the tests were significantly higher in the patients with COVID-19, which suggests that global FM symptoms are more severe in patients with infection. Further studies of the post-COVID19 patients are being carried out in order to discover whether the worsened symptomatology continues because of their hypersensitised state.

Rheumatology Article